Amyloid antibodies against

Bard, F., Cannon, C., Barbour, R. et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med. 6 916-919,2000. 

Hock, C., Konietzko, U., Streffer, J. R. et al. Antibodies against (3-amyloid slow cognitive decline in Alzheimer s disease. Neuron 38 547-554,2003. 

Bard, F., Cannon, C., Barbour, R., Burke, R. L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., et al. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Mat. Med. 6, 916-919. 

DIFFERENTIAL EPITOPE IDENTIFICATION OF ANTIBODIES AGAINST INTRACELLULAR DOMAINS OF ALZHEIMER S AMYLOID PRECURSOR PROTEIN USING HIGH RESOLUTION AFFINITY-MASS SPECTROMETRY... 

Differential Epitope Identification of Antibodies Against Intracellnlar Domains of Alzheimer s Amyloid Precursor... 

Umbiicht D, de Quervain DJ, Hofmann M, Maddalena A, Papassoti-ropoulos A, Nitsch RM (2003) Antibodies against beta amyloid slow cognitive dechne in Alzheimer s disease. Neuron 38(4) 547-554. 

Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A, Hem-meter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A, Nolker C, Moller HJ, Wei X, Farlow M, Sommer N, Oertel WH (2004) Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer s disease. J Neurol Neuro-surg Psychiatry 75 1472-1474. 

McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, French JE, Lambermon MH, Darabie AA, Brown ME, Janus C, Chishti MA, Home R Westaway D, Fraser PE, Mount HT, Przybyl-ski M, George-Hyslop P (2002) Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4—10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8 1263-1269. 

Tian, X., Cecal, R., Mezo, G., Manea, M., Stefanescu, R., McLaurin, J., St George-Hyslop, R, Hudecz, F. and Przybylski, M. (2004) New amyloid-derived vaccine lead stmctures against Alzheimer s disease discovered by affinity proteomics and high resolution mass spectrometry. In Innovation and Perspectives in Antibody and Peptide Vaccine Development, R. Epton, ed. (Kingswinford, UK Mayflower Worldwide Ltd), p. 79. 

There are several other metabolic disorders, but because they are not very common, not much is known about them. For example, a disease known as amyloidosis results when enough amyloid protein builds up in one or more organs to cause the organ(s) to malfunction. The heart, kidneys, nervous system and gastrointestinal tract are most often affected. Amyloid (pronounced am -i-loyd) is an abnormal protein that may be deposited in any of the body s tissues or organs. This abnormal protein comes from cells in the bone marrow, so amyloidosis is known as a bone marrow disease. The bone marrow makes protective antibodies that protect against infection and disease. After they have served their function, these antibodies are broken down and recycled by... 

Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T (2003) Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer s disease-like neuropathology. Proc Natl Acad Sci USA 100 2023-2028. 

---